124 related articles for article (PubMed ID: 8983938)
1. In vivo stability and excretion of gadodiamide (GdDTPA-BMA), a hydrophilic gadolinium complex used as a contrast enhancing agent for magnetic resonance imaging.
Normann PT; Hals PA
Eur J Drug Metab Pharmacokinet; 1995; 20(4):307-13. PubMed ID: 8983938
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and stability of caldiamide sodium in rats.
Okazaki O; Kurata T; Yoshioka N; Hakusui H
Arzneimittelforschung; 1996 Jan; 46(1):79-83. PubMed ID: 8821523
[TBL] [Abstract][Full Text] [Related]
3. Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent.
Harpur ES; Worah D; Hals PA; Holtz E; Furuhama K; Nomura H
Invest Radiol; 1993 Mar; 28 Suppl 1():S28-43. PubMed ID: 8486501
[TBL] [Abstract][Full Text] [Related]
4. Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats.
Tweedle MF; Wedeking P; Kumar K
Invest Radiol; 1995 Jun; 30(6):372-80. PubMed ID: 7490190
[TBL] [Abstract][Full Text] [Related]
5. Impact of Treatment With Chelating Agents Depends on the Stability of Administered GBCAs: A Comparative Study in Rats.
Boyken J; Frenzel T; Lohrke J; Jost G; Schütz G; Pietsch H
Invest Radiol; 2019 Feb; 54(2):76-82. PubMed ID: 30358694
[TBL] [Abstract][Full Text] [Related]
6. Detection and quantitation of gadolinium chelates in human serum and urine by high-performance liquid chromatography and post-column derivatization of gadolinium with Arsenazo III.
Hvattum E; Normann PT; Jamieson GC; Lai JJ; Skotland T
J Pharm Biomed Anal; 1995 Jun; 13(7):927-32. PubMed ID: 8562618
[TBL] [Abstract][Full Text] [Related]
7. Placental transfer and milk secretion of gadodiamide injection in rats.
Okazaki O; Murayama N; Masubuchi N; Nomura H; Hakusui H
Arzneimittelforschung; 1996 Jan; 46(1):83-6. PubMed ID: 8821524
[TBL] [Abstract][Full Text] [Related]
8. Gadodiamide in renal transplant patients: effects on renal function and usefulness as a glomerular filtration rate marker.
Berg KJ; Lundby B; Reinton V; Nordal KP; Rootwelt K; Smith HJ
Nephron; 1996; 72(2):212-7. PubMed ID: 8684529
[TBL] [Abstract][Full Text] [Related]
9. Gadodiamide injection. First human experience with the nonionic magnetic resonance imaging enhancement agent.
Van Wagoner M; Worah D
Invest Radiol; 1993 Mar; 28 Suppl 1():S44-8. PubMed ID: 8486503
[TBL] [Abstract][Full Text] [Related]
10. Cerebrovascular transit characteristics of DyDTPA-BMA and GdDTPA-BMA on normal and ischemic cat brain.
Kucharczyk J; Asgari H; Mintorovitch J; Vexler Z; Rocklage S; Watson A; Moseley M
AJNR Am J Neuroradiol; 1993; 14(2):289-96. PubMed ID: 8456701
[TBL] [Abstract][Full Text] [Related]
11. Comparative transmetallation kinetics and thermodynamic stability of gadolinium-DTPA bis-glucosamide and other magnetic resonance imaging contrast media.
Puttagunta NR; Gibby WA; Puttagunta VL
Invest Radiol; 1996 Oct; 31(10):619-24. PubMed ID: 8889650
[TBL] [Abstract][Full Text] [Related]
12. Interference of gadodiamide injection (OMNISCAN) on the colorimetric determination of serum calcium.
Normann PT; Frøysa A; Svaland M
Scand J Clin Lab Invest; 1995 Aug; 55(5):421-6. PubMed ID: 8545600
[TBL] [Abstract][Full Text] [Related]
13. Biliary excretion and pharmacokinetics of a gadolinium chelate used as a liver-specific contrast agent for magnetic resonance imaging in the rat.
Schuhmann-Giampieri G; Schmitt-Willich H; Frenzel T; Schitt-Willich H [corrected to Schmitt-Willich H]
J Pharm Sci; 1993 Aug; 82(8):799-803. PubMed ID: 8377117
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics in rats, dogs and monkeys of a gadolinium chelate used as a liver-specific contrast agent for magnetic resonance imaging.
Schuhmann-Giampieri G; Frenzel T; Schmitt-Willich H
Arzneimittelforschung; 1993 Aug; 43(8):927-31. PubMed ID: 8216456
[TBL] [Abstract][Full Text] [Related]
15. The use of a binary chelate formulation: Could gadolinium based linear contrast agents be rescued by the addition of zinc selective chelates?
Gibby W; Parish W; Merrill RM; Fernandez D; Anderson CR; Merchel E; Parr R
Magn Reson Imaging; 2019 May; 58():76-81. PubMed ID: 30639754
[TBL] [Abstract][Full Text] [Related]
16. Human in vivo comparative study of zinc and copper transmetallation after administration of magnetic resonance imaging contrast agents.
Puttagunta NR; Gibby WA; Smith GT
Invest Radiol; 1996 Dec; 31(12):739-42. PubMed ID: 8970874
[TBL] [Abstract][Full Text] [Related]
17. A phase I clinical trial with gadodiamide injection, a nonionic magnetic resonance imaging enhancement agent.
VanWagoner M; O'Toole M; Worah D; Leese PT; Quay SC
Invest Radiol; 1991 Nov; 26(11):980-6. PubMed ID: 1743922
[TBL] [Abstract][Full Text] [Related]
18. Contrast-enhanced MRI with gadodiamide injection in rat disease models.
Yamada K; Miyahara K; Sato H; Nakayama W; Sato M; Hirose T; Kato H; Ikehira H; Tateno Y; Sugihara H; Furuhama K
J Vet Med Sci; 1996 Apr; 58(4):291-5. PubMed ID: 8741259
[TBL] [Abstract][Full Text] [Related]
19. Comparative in vivo dissociation of gadolinium chelates in renally impaired rats: a relaxometry study.
Fretellier N; Idée JM; Dencausse A; Karroum O; Guerret S; Poveda N; Jestin G; Factor C; Raynal I; Zamia P; Port M; Corot C
Invest Radiol; 2011 May; 46(5):292-300. PubMed ID: 21263333
[TBL] [Abstract][Full Text] [Related]
20. Determination of dysprosium in monkey serum by inductively-coupled plasma atomic emission spectrometry (ICP-AES) after the administration of Sprodiamide Injection, a new contrast medium for magnetic resonance imaging.
Lai JJ; Jamieson GC
J Pharm Biomed Anal; 1993; 11(11-12):1129-34. PubMed ID: 8123724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
